Tyler Technologies (TYL) shares came under pressure after fourth quarter and full year 2025 results missed analyst expectations, and 2026 revenue guidance landed below both historical growth rates and ...
CEO Steven Basta told attendees at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company’s commercial focus over the past year has shifted more heavily toward gastroenterology, a move h ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results